MGI Tech's Strategic Collaboration with Swiss Rockets AG
MGI Tech Co., Ltd. (“MGI”), a pioneering company known for developing essential tools in life sciences, has embarked on a significant journey through an exclusive licensing alliance with Swiss Rockets AG. This partnership will focus on enhancing the reach of MGI's proprietary CoolMPSä sequencing technology, aiming to expand its global footprint beyond the Asia-Pacific and Greater China regions.
Innovative Sequencing Technology: CoolMPSä
At the core of this collaboration lies the CoolMPS technology, which stands out with its distinctive antibody-based recognition chemistry. This groundbreaking innovation eliminates the common issue of DNA "scarring" found in traditional long-read sequencing methods. The approach utilizes nucleotides with natural bases along with specific labeled antibodies that enhance the accuracy and reliability of sequencing results.
Implemented on MGI’s advanced DNBSEQä platforms, CoolMPS technology can produce sequencing reads between 600 and 700 bases. This capability supports extensive genome, transcriptome, and microbiome analyses, making it an invaluable asset for researchers focusing on early cancer detection and monitoring through comprehensive genomic assays. The technology not only enhances the accuracy of readings but also significantly reduces the costs associated with genomic sequencing.
Exclusive Rights and Global Commercialization
The exclusive rights bestowed upon Swiss Rockets AG under this licensing agreement empower them to utilize MGI's CoolMPS-related intellectual properties. This includes vital patents and software, enabling Swiss Rockets to develop and commercialize products tailored for markets outside Asia-Pacific and Greater China. This partnership is essential for unlocking the commercial potential of CoolMPS, as it enhances MGI's leadership position within the genomic sequencing domain.
With support from significant investments, particularly from Emergent BioSolutions, Swiss Rockets will harness the advantages of the CoolMPS licensing agreement to manufacture sequencers and consumables targeted at the US and European markets. This strategic move is not solely focused on sequencing technology; it also plays a crucial role in augmenting their personalized medical solutions aimed at disease prevention and optimized treatments.
Leadership Insights on the Partnership
Dr. Rade Drmanac, the Chief Scientific Officer at MGI, emphasizes the importance of this partnership, stating that it is a crucial step in enhancing the global impact of CoolMPS. By collaborating with an innovative partner like Swiss Rockets, MGI aims to commercialize and scale this revolutionary technology for broader health benefits. He also mentioned that this partnership underscores MGI's financial stability and unwavering focus on technological advancement, reminding customers, partners, and investors that MGI provides them with multifaceted solutions in life sciences.
In agreement, Dr. Vladimir Cmiljanovic, the CEO of Swiss Rockets, expressed enthusiasm about acquiring the CoolMPS licensing rights. He highlighted how this will propel their mission in oncology and viral disease innovations, combining world-class technology with their ongoing drug development initiatives, ensuring tailored health solutions for communities.
About MGI Tech Co., Ltd.
MGI Tech Co., Ltd., along with its subsidiaries, remains committed to delivering cutting-edge tools and technological advancements in life sciences. Their dedicated focus on research, development, manufacturing, and sales positions them as a key player in biotechnology. MGI offers a comprehensive array of digital equipment and multi-omics systems designed for precision medicine, agricultural applications, and various industries.
About Swiss Rockets AG
Swiss Rockets AG functions both as an incubator and accelerator for biotech and precision healthcare startups, particularly in oncology. The company boasts a portfolio featuring radioligand therapies, small molecules, and vaccines currently in pre-clinical and clinical stages, attracting considerable interest from top global pharmaceutical firms for potential collaborations.
Frequently Asked Questions
What is the significance of the CoolMPS technology in genomics?
CoolMPS technology signifies a substantial advancement in sequencing accuracy and efficiency, with the ability to generate long, reliable reads essential for genomic and transcriptomic analyses.
How does the partnership with Swiss Rockets AG benefit MGI?
This partnership expands MGI's market reach, enhancing the commercialization of CoolMPS technology globally while reinforcing MGI's leadership and financial strength in life sciences.
What are the applications of CoolMPS technology?
CoolMPS technology is crucial in genome sequencing for applications such as early cancer detection and monitoring, providing high-quality, cost-effective solutions for researchers.
What role does Swiss Rockets AG play in this partnership?
Swiss Rockets AG is responsible for commercializing the CoolMPS products in global markets, leveraging the licensing rights to manufacture sequencers and related consumables.
When was MGI Tech founded?
MGI Tech was founded in 2016 and has since become a leader in the life sciences field, delivering innovative products and services worldwide.
